MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Medpace Holdings Inc

Slēgts

SektorsVeselības aprūpe

302.47 3.93

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

284.67

Max

303.22

Galvenie mērījumi

By Trading Economics

Ienākumi

21M

117M

Pārdošana

3.3M

537M

P/E

Sektora vidējais

22.077

57.333

EPS

3.67

Peļņas marža

21.808

Darbinieki

5,900

EBITDA

-916K

125M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+7.04% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 21. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

9B

Iepriekšējā atvēršanas cena

298.54

Iepriekšējā slēgšanas cena

302.47

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Medpace Holdings Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. apr. 23:54 UTC

Karstas akcijas

Stocks to Watch: Alphabet, Intel, AppFolio

2025. g. 24. apr. 23:51 UTC

Tirgus saruna

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

2025. g. 24. apr. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. apr. 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025. g. 24. apr. 23:37 UTC

Top Ziņas

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

2025. g. 24. apr. 23:36 UTC

Top Ziņas

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

2025. g. 24. apr. 23:13 UTC

Top Ziņas
Peļņas

Google's Earnings Power Holds Up in Global Turbulence -- Update

2025. g. 24. apr. 23:09 UTC

Top Ziņas

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

2025. g. 24. apr. 23:02 UTC

Iegādes, apvienošanās, pārņemšana

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

2025. g. 24. apr. 23:02 UTC

Iegādes, apvienošanās, pārņemšana

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

2025. g. 24. apr. 22:51 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

2025. g. 24. apr. 22:48 UTC

Top Ziņas

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

2025. g. 24. apr. 22:47 UTC

Tirgus saruna

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

2025. g. 24. apr. 22:38 UTC

Tirgus saruna
Peļņas

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

2025. g. 24. apr. 22:24 UTC

Peļņas

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

2025. g. 24. apr. 22:24 UTC

Peļņas

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

2025. g. 24. apr. 22:24 UTC

Tirgus saruna
Peļņas

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

2025. g. 24. apr. 22:23 UTC

Peļņas

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

2025. g. 24. apr. 22:11 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 24. apr. 22:11 UTC

Tirgus saruna
Peļņas

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

2025. g. 24. apr. 22:09 UTC

Top Ziņas
Peļņas

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

2025. g. 24. apr. 22:00 UTC

Tirgus saruna
Peļņas

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

2025. g. 24. apr. 21:39 UTC

Top Ziņas

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

2025. g. 24. apr. 21:24 UTC

Top Ziņas
Peļņas

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025. g. 24. apr. 21:24 UTC

Top Ziņas
Peļņas

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

2025. g. 24. apr. 21:23 UTC

Top Ziņas
Peļņas

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

2025. g. 24. apr. 21:04 UTC

Peļņas

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

2025. g. 24. apr. 21:03 UTC

Peļņas

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

2025. g. 24. apr. 21:03 UTC

Peļņas

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

2025. g. 24. apr. 21:02 UTC

Peļņas

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Salīdzinājums

Cenas izmaiņa

Medpace Holdings Inc Prognoze

Cenas mērķis

By TipRanks

7.04% augšup

Prognoze 12 mēnešiem

Vidējais 311 USD  7.04%

Augstākais 355 USD

Zemākais 283 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Medpace Holdings Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

7 ratings

1

Pirkt

6

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

285.0378 / 305.315Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Medpace Holdings Inc

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.